Attached files
file | filename |
---|---|
EX-23.1 - EXHIBIT 23.1 - PDS Biotechnology Corp | ex23_1.htm |
EX-31.2 - EXHIBIT 31.2 - PDS Biotechnology Corp | ex31_2.htm |
EX-32.2 - EXHIBIT 32.2 - PDS Biotechnology Corp | ex32_2.htm |
EX-10.3 - EXHIBIT 10.3 - PDS Biotechnology Corp | ex10_3.htm |
EX-31.1 - EXHIBIT 31.1 - PDS Biotechnology Corp | ex31_1.htm |
10-K - EDGE THERAPEUTICS, INC. 10-K 12-31-2015 - PDS Biotechnology Corp | form10k.htm |
Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Annual Report of Edge Therapeutics, Inc. (the “Company”), on Form 10-K for the year ended December 31, 2015 (the “Report”), I, Brian A. Leuthner, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:
(1) | the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: March 8, 2016
|
/s/ Brian A. Leuthner
|
Brian A. Leuthner
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|